Submit your claim details for a free, no obligation case review
Get Started:
In September 2003, the FDA decided Zyprexa labeling changes needed to be made. This decision was the result of a multi year review of all available data, including case reports, epidemiologic studies, and clinical trial data. The new Zyprexa labeling warns of diabetes risks that have surfaced amongst second-generation antipsychotics like Zyprexa. The American Diabetes Association issued an option paper regarding the diabetes risk, which Lilly does not agree with. Lilly is worried the paper does not acknowledge the benefits Zyprexa does have.